MAVS CRISPR/Cas9 KO Plasmid (h2): sc-400769-KO-2

Overview

MAVS (mitochondrial antiviral signaling protein; IPS-1/VISA/Cardif) is a mitochondria-associated adaptor that couples cytosolic viral RNA sensing by RIG-I (DDX58) and MDA5 (IFIH1) to downstream innate immune signaling. Upon activation, MAVS assembles higher-order complexes that recruit TRAF adaptors and activate TBK1/IKKε and the IKK complex, driving IRF3/IRF7 and NF-κB transcriptional programs that induce type I interferons and inflammatory cytokines. MAVS activity shapes antiviral restriction, apoptosis, and immunometabolic responses, and is a common target of viral immune evasion mechanisms. Dysregulated MAVS-dependent signaling has been linked to aberrant interferon responses and inflammatory pathology, making it a key node for studying host–pathogen interactions and innate immune regulation in human cells.

MAVS CRISPR/Cas9 KO Plasmid (h2) is a pool of plasmids designed for targeted disruption of the MAVS gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the MAVS locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.

When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.

Homology-Directed Repair (HDR) Donor — Puromycin Cassette with RFP Reporter

For applications requiring confirmed, selectable knockout clones, MAVS HDR Plasmid (h2) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined MAVS target site.
When co-transfected with MAVS CRISPR/Cas9 KO Plasmid (h2):

• The PuroR-RFP cassette integrates at the Cas9 cut site via HDR, disrupting the MAVS open reading frame.
• RFP fluorescence provides an immediate visual indicator of successful integration, enabling fluorescence-based identification or sorting of edited cells prior to or alongside puromycin selection.
• Successfully edited cells are confirmed through puromycin resistance, substantially reducing clone screening burden.
• This selection strategy is ideal for generating stable, clonal KO cell lines for downstream functional studies, drug screening, or model development.

Cre-lox Cassette Removal System

The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the MAVS locus and eliminating potential confounding effects on downstream assays.
This two-step approach:

• Minimizes disruption to local chromatin architecture and neighboring regulatory elements
• Restores a near-native genomic context at the edited locus
• Enables reuse of the puromycin selection strategy in the same cell line for additional edits

Key Features

• gRNA targeting MAVS exon(s) critical for MAVS function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• HDR donor with puromycin resistance for positive clone selection
• loxP-flanked PuroR cassette with Cre recombinase vector for seamless marker removal
• Supplied ready to use for delivery by transfection

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.